Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Current Leases (2019 - 2025)

Historic Current Leases for Protalix BioTherapeutics (PLX) over the last 7 years, with Q3 2025 value amounting to $1.4 million.

  • Protalix BioTherapeutics' Current Leases fell 736.07% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 736.07%. This contributed to the annual value of $1.5 million for FY2024, which is 645.85% up from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Current Leases stood at $1.4 million, which was down 736.07% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Current Leases ranged from a high of $1.5 million in Q3 2024 and a low of $1.0 million during Q3 2022
  • In the last 5 years, Protalix BioTherapeutics' Current Leases had a median value of $1.3 million in 2023 and averaged $1.3 million.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Current Leases plummeted by 1902.83% in 2022, and later skyrocketed by 3130.0% in 2023.
  • Protalix BioTherapeutics' Current Leases (Quarter) stood at $1.2 million in 2021, then dropped by 7.37% to $1.1 million in 2022, then grew by 26.03% to $1.4 million in 2023, then increased by 6.46% to $1.5 million in 2024, then dropped by 6.87% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.5 million for Q2 2025, and $1.4 million during Q1 2025.